Phase II Biotransformation: Glucuronidation and Conjugation Reactions
Phase II detoxification (hepatic conjugation reactions converting lipophilic compounds to polar water-soluble metabolites for renal/biliary excretion): glucuronidation (most abundant Phase II pathway; ~35% of drug metabolism): UGT (UDP-glucuronosyltransferase; ER-localised; 19 human UGTs (UGT1A family: UGT1A1 (bilirubin/oestrogens/irinotecan/SN-38 glucuronidation; UGT1A1*28 polymorphism: reduced activity → Gilbert's syndrome/irinotecan toxicity); UGT1A3/4/6/9/10; UGT2B family: UGT2B7 (morphine/hydromorphone/NSAIDs; highest hepatic expression); UGT2B15/17 (androgens/oestrogens)); catalytic: UDP-glucuronic acid (UDPGA; from glucose-1-phosphate → UGP2 → UDP-glucose → UGDH (UDP-glucose dehydrogenase) → UDPGA) + substrate (OH/NH2/COOH group) → O/N/C-glucuronide + UDP; product: glucuronide (water-soluble; anionic; MRP2/MDR3 → biliary excretion or OAT3 → renal); sulphation (SULT; cytosolic; PAPS (3′-phosphoadenosine-5′-phosphosulphate; from ATP + SO42−; PAPSS1/2) donor; SULT1A1 (phenol/catechol; tyrosine metabolites); SULT1E1 (oestrogen; high-affinity E1/E2 sulphation; inactivation); SULT2A1 (DHEA/androgen); rapid but saturable at high substrate); GST (glutathione S-transferase; GSTA1/2/P1/M1; electrophile → GSH conjugation → mercapturic acid; NRF2-ARE maximum upregulation); glucuronidation substrates: bilirubin, oestrogens (E1/E2/E3), testosterone, THC/cannabinoids, SN-38 (irinotecan active metabolite), tamoxifen, resveratrol, quercetin.
Spirulina Mechanisms in Phase II Detoxification
Nrf2-Driven UGT Induction
UGT transcription (NRF2/ARE: all UGT1A subfamily members have ARE elements in promoters; Nrf2 → UGT1A1/1A3/1A6/1A9 transcription; NF-κB (inverse regulation: NF-κB → repression of UGT1A1 promoter via C/EBPβ displacement); AhR (xenobiotic receptor; AhR/ARNT → XRE in UGT1A1/1A6 promoter; AhR ligands (phycocyanobilin; dietary indoles; PAH) → UGT1A induction; AhR-Nrf2 crosstalk: shared ARE/XRE proximity at UGT1A loci); PXR (pregnane X receptor; rifampin/St John's Wort → PXR → CYP3A4/UGT1A1 induction); CAR (constitutive androstane receptor; phenobarbital → CAR → UGT1A1)) is activated by spirulina: (1) Nrf2 (phycocyanin/isothiocyanate-like metabolites → Keap1 Cys151/273/288 modification → Nrf2 nuclear translocation → ARE binding; UGT1A1 ARE activation +15–30%); (2) AhR (phycocyanobilin tetrapyrrole → AhR binding KD ~1–10 µM → AhR/ARNT → XRE → UGT1A1/1A6; similar to indole-3-carbinol/DIM mechanism); (3) NF-κB suppression (−30–45%) → NF-κB-UGT1A1 repression removed → UGT1A1 derepressed. UGT1A1 mRNA +15–30% (Hep-G2/primary hepatocyte models); UGT2B7 +10–20%. Phenotypic marker: plasma bilirubin (UGT1A1 substrate) slight decrease (−5–10%) in euglycaemic/metabolic models; oestrogen glucuronide +15–25% in urine (indirect UGT1A1 activity).
SULT1A1/SULT1E1 Sulphotransferase Support
SULT1E1 (oestrogen sulphotransferase; highest affinity for oestrone/17β-oestradiol; Km ~1–5 nM E2; sulphation → E1-SO4/E2-SO4 (biologically inactive; water-soluble; renal excretion); SULT1E1 knockdown → oestrogen accumulation → ERα-driven proliferation; SULT1E1 reduced in: obesity (adipose TNF-α → SULT1E1 ↓); NASH; NF-κB activation); SULT1A1 (catecholamine/tyrosine metabolite/xenobiotic phenols/aspirin metabolites sulphation); PAPS (3′-phosphoadenosine-5′-phosphosulphate; PAPSS1 in liver/ER; PAPSS2 in adrenal/testis; substrate; limited intracellular pool; dietary sulphur amino acids (Met/Cys) provide sulphate via SUOX (sulphite oxidase) → SO42−)) is supported by spirulina: (1) NF-κB suppression → TNF-α −20–35% → SULT1E1 derepression (NF-κB/TNF-α → SULT1E1 promoter repression via NFκB response element); (2) Nrf2 → SULT1A1 (ARE-driven; NQO1 and SULT1A1 share ARE promoter architecture; Nrf2 → SULT1A1 +10–20%); (3) sulphate provision: spirulina Met content (0.25g/10g) → Met oxidation → sulphate → PAPSS → PAPS pool support; (4) tyrosine/phenylalanine (spirulina ~2.5g Phe+Tyr/100g protein) → SULT1A1 catecholamine sulphation substrate. SULT1E1 activity preservation → oestrogen inactivation pathway maintained (relevant for hormone-dependent cancer risk).
GSTA1/GSTP1 Glutathione S-Transferase Induction
GST (glutathione S-transferase; major Phase II enzyme superfamily; Alpha (GSTA1/2; liver-predominant; lipid peroxidation products/4-HNE; CDNB standard substrate); Pi (GSTP1; ubiquitous; JNK inhibitory complex: GSTP1-JNK1 interaction keeps JNK inactive; GSTP1 overexpression in cancer → drug resistance); Mu (GSTM1; null polymorphism ~50% Caucasians → reduced lung/colorectal cancer protection); Theta (GSTT1; null ~20%); Sigma (GSTS1; PGD2 synthesis; PGH2 → PGD2); GSTZ1 (isomerisation; tyrosine catabolism)); NRF2/ARE activation → GSTA1/2/P1/M1 transcription (ARE in GSTA1/2 promoters; GSTA1 quintessential Nrf2 target; 5–10× inducible); substrates: 4-HNE (4-hydroxynonenal; lipid peroxidation end-product; GST → 4-HNE-GS conjugate → mercapturic acid urine); acrolein (smoke); chlorambucil; melphalan; cisplatin; CDNB) is induced by spirulina: Nrf2 activation → GSTA1 +25–40% (consistent finding in spirulina/phycocyanin-treated hepatocyte models; among the most reproducible Phase II effects); GSTP1 +15–25%; GSTM1 +10–20% (compensatory in GSTM1-null context). 4-HNE protein adducts −20–35% (→ reduced lipid peroxidation protein damage); NAPQI (paracetamol toxic metabolite; CYP2E1 → NAPQI; GST → NAPQI-GS; spirulina GSTA1 → increased NAPQI detoxification capacity → hepatoprotective at moderate paracetamol doses).
UDPGA Co-Substrate and MRP2 Biliary Transport
UDPGA (UDP-glucuronic acid; UGT co-substrate; synthesised from glucose-1-P → UGP2 → UDP-glucose → UGDH (UDP-glucose dehydrogenase; 2 NAD+ oxidations) → UDPGA; UGDH is NAD+-dependent; limited by: cellular NAD+ availability (AMPK/SIRT1 → NAD+); hexose-phosphate pool; hormonal regulation (insulin → UGDH ↑; glucagon → UGDH ↓); ER import (UGT in ER lumen; UDPGA import by SLC35D1 antiporter)); MRP2 (multidrug resistance-associated protein 2; ABCC2; canalicular bile efflux; glucuronide/GSH-S/sulphate conjugate export into bile; Nrf2/ARE in MRP2 promoter; inducible by xenobiotics; deficiency → Dubin-Johnson syndrome; MRP2 → glucuronide → bile → gut → deconjugation (gut β-glucuronidase) → enterohepatic recirculation (EHC) of oestrogens/bilirubin/drugs)) is enhanced by spirulina: (1) AMPK → NAD+ elevation → UGDH → UDPGA cofactor pool support; (2) pentose phosphate pathway (AMPK ↓ PFKFB3 → reduces glycolysis flux relative to PPP → more glucose-6-P available for UDP-glucose → UDPGA); (3) Nrf2 → MRP2 +10–20% (biliary glucuronide efflux → conjugate elimination); (4) gut microbiome (spirulina prebiotic → reduced β-glucuronidase activity from dysbiotic Firmicutes → less EHC of oestrogen/glucuronides → net better oestrogen clearance). MRP2 protein +10–20%; total biliary glucuronide output +10–20%.
Clinical Outcomes in Phase II Detoxification
- UGT1A1 mRNA/activity (hepatocyte models; 5–7 days): +15–30%
- GSTA1 protein (liver; Nrf2 target; primary): +25–40%
- Urinary oestrogen glucuronides (E1G/E2G; women): +15–25%
- 4-HNE protein adducts (lipid peroxidation GST substrate): −20–35%
- MRP2 (biliary efflux; hepatocyte): +10–20%
- Plasma bilirubin (UGT1A1 functional marker; mild): −5–10%
Dosing and Drug Interactions
Hepatic detoxification/oestrogen clearance/environmental toxin exposure: 5–10g daily; cruciferous vegetables (I3C/DIM: also AhR/Nrf2 → UGT1A1) synergise with spirulina. Irinotecan (SN-38 glucuronidation by UGT1A1): Spirulina UGT1A1 induction → faster SN-38 glucuronidation → reduced SN-38 exposure → potentially reduced irinotecan efficacy AND toxicity; do not co-administer with chemotherapy without oncologist supervision; UGT1A1 inducers are clinically significant. Morphine (UGT2B7 → morphine-6-glucuronide; active analgesic): UGT2B7 induction → faster morphine-6-glucuronide formation (M6G; more potent analgesic) vs. morphine-3-glucuronide (M3G; neuroexcitatory); complex net effect; monitor pain management. Tamoxifen (UGT2B7/UGT1A4 N-glucuronidation): Spirulina UGT induction may accelerate tamoxifen glucuronidation → reduced active tamoxifen exposure; caution in breast cancer tamoxifen therapy. Oral contraceptives (oestrogen/progestin; UGT1A1/SULT1E1 substrates): Accelerated OCP metabolism theoretically possible; monitor breakthrough bleeding (indicator of reduced OCP efficacy). Summary: UGT1A1 +15–30%, GSTA1 +25–40%, oestrogen-glucuronides +15–25%; dosing 5–10g daily. NK concern: UGT1A1 induction clinically significant for irinotecan/tamoxifen/OCP interactions; consult prescriber.